Bilin Star Ventures Closes First Tranche of Its Phase II RMB Fund to Advance MedTech Innovations Addressing Critical Clinical Needs

Proxima Capital’s Phase II RMB Venture Capital Fund Achieves First Close, Adding Multiple Medical Technology Innovation Companies to Its Portfolio

Proxima Capital, established in July 2016, focuses on the healthcare industry and serves exceptional medical technology innovation enterprises with significant growth potential. The fund’s core team members all have backgrounds in medical industrialization, having spent many years engaged in R&D, indication development, marketing, or investment and acquisitions at internationally leading companies such as Philips, ERBE, Boston Scientific, Johnson & Johnson, Medtronic, Pfizer, and Novartis. One of the founders has previously invested in and supported six companies that successfully achieved IPOs, while the other founder has incubated nearly 100 overseas medical innovation teams, delivering outstanding performance.

The core team possesses a global perspective and an international network of medical resources, demonstrating outstanding industry research capabilities and the ability to identify high-quality projects worldwide. It also boasts top-tier clinical medical resources and strong industrialization capabilities. Proxima Capital has established five international medical innovation and translation bases across China and forged close collaborations with leading hospitals nationwide to facilitate the clinical translation of innovative medical technologies. The platform provides end-to-end services for medical startups, including patent strategy, R&D, clinical trials, regulatory approval, and assistance with cGMP-certified production facilities.

During the fundraising process for its Phase II venture capital fund, Proxima Capital secured support from healthcare-focused institutional investors, including government guidance funds, healthcare-specific fund-of-funds, healthcare asset management firms, and publicly listed healthcare companies.

Proxima Capital’s Phase I RMB Fund has invested in 17 innovative enterprises, with lead investments and board seats in 13 of them. Currently, the vast majority of its portfolio companies have emerged as leaders in their respective niche sectors. Proxima Capital’s previous investment portfolio includes:

• Ningbo Jianshi Biotechnology Co., Ltd.: China’s original, globally leading transcatheter tricuspid valve replacement product, which has treated over 40 critically ill patients; innovative tricuspid valve repair products; mitral valve replacement and repair products with favorable long-term outcomes; and aortic valve products that address both regurgitation and stenosis.

• Kangfeng Biotechnology (Shanghai) Co., Ltd.: A globally leading, China-originated cryoablation technology for cardiovascular diseases. Featuring natural gas, low pressure, and easy controllability, it delivers superior efficacy. Two products targeting atrial fibrillation and hypertension have entered the innovative approval pathway and are currently undergoing clinical trials.

• Aico Medical Devices (Beijing) Co., Ltd. has pioneered the first domestically developed flow diverter stent for hemorrhagic stroke, featuring technological innovations and is poised to initiate clinical trials; as well as an innovative aspiration catheter for ischemic stroke

• Wuhan Weike Medical Technology Co., Ltd.: Patent Foramen Ovale (PFO) Occluder for the Treatment of Cryptogenic Stroke, and an Innovative Heart Failure Shunt Device

• Suzhou Langkai Medical Technology Co., Ltd.: The only approved next-generation magnetic navigation platform in Eurasia, featuring three channels, local anesthesia, and compatibility with all surgical procedures, ranking among the global leaders; multiple therapeutic products are undergoing clinical trials sequentially, and surgical robots are under development; as a key national special project, organized by the Ministry of Science and Technology, it has conducted the world’s largest-scale demonstration and promotion clinical trial involving dozens of hospitals with over 2,000 cases; building the world’s largest open platform for pulmonary diagnosis and treatment.

• Ningbo Shengjie Kang Biotechnology Co., Ltd. has pioneered four therapeutic products globally for lung cancer, COPD, asthma, and benign/malignant airway stenosis, and five therapeutic products domestically in gastroenterology and urology. Some of these products have obtained CFDA registration certificates.

• Hangzhou Ruidi Biotechnology Co., Ltd.: Irreversible cell perforation triggering an immune response to eliminate tumors; next-generation nanosecond pulsed electric field (nsPEF) technology surpassing NanoKnife®; Major National Science and Technology Project; the world’s first tumor interventional therapy of its kind to enter clinical trials, with a focus on liver cancer and pancreatic cancer.

• Zhejiang MedPace Medical Technology Co., Ltd., a global leader in neuromodulation platforms for gastrointestinal and metabolic diseases, possesses a portfolio of globally innovative diagnostic, wearable, and implantable products, some of which have obtained CFDA registration certificates.

• Hangzhou Tangji Medical Technology Co., Ltd.: Innovative Minimally Invasive Therapeutic Devices and Breakthrough Solutions Undergoing Clinical Trials, Focused on Weight Loss, Diabetes, and NASH

• Shenzhen Zifu Medical Technology Co., Ltd.: Capsule gastroscopy with independent intellectual property rights and leading technology; excellent clinical trial and follow-up results; CFDA registration certificate expected to be obtained in the near future.

• Shanghai Xinjian Medical Technology Co., Ltd. possesses in-depth expertise in personalized orthopedic design and major national special projects. It is the second company globally and the only one in China to obtain a CFDA registration certificate for medical 3D printing software. Six of its consumable products have also received CFDA registration certificates. The company is the sole domestic enterprise whose software systems and related consumables have been integrated into the cooperation and procurement network of the world’s largest industry player.

• Beijing Bohui Ruijin Biotechnology Co., Ltd. possesses two core technology platforms: regenerative materials and innovative biological tissue adhesives. As a recipient of major national special projects, the company has achieved global innovation with multiple products and has applied for more than 10 registration certificates for Class III implantable biomaterials and over 20 registration certificates for innovative medical devices.

• Epibone Inc., a leading regenerative medicine company, has launched clinical trials for its stem cell-induced bone repair product—the only one of its kind globally to have received U.S. FDA approval to date—marking a significant breakthrough in the field of engineered tissues and organs.

• Shanghai Kunyuan Biotechnology Co., Ltd. is a global leader in methylation detection, cancer origin tracing, and single-cell sequencing technologies. Holding core intellectual property rights worldwide, the company has published multiple papers in prestigious journals such as Nature Genetics, garnering significant global attention. It is poised to achieve a breakthrough in early cancer screening on a global scale.

• Sena Biotechnology (Beijing) Co., Ltd.: Sequencers for Clinical Applications with Full Independent Intellectual Property Rights

• HiFiBio (HK) Limited (Gaocheng Bio), equipped with a globally leading antibody development platform and single-cell analysis technology, has developed nearly 10 innovative antibody drugs in the fields of cancer and autoimmune diseases while providing CRO services.

• Hangzhou Daihu Information Technology Co., Ltd. has become a leading enterprise in China’s internet-based mental health service platform sector. Its flagship platform, Yidianling, boasts over 3 million registered users and more than 13,000 licensed psychological counselors. The platform has accumulated over 200 million minutes of paid consultation time and 1.2 million hours of pro bono service, helping more than 150,000 families in conflict resolve their difficulties.